Reproductive Carrier Screening Detects Early Actionable Metabolic Conditions

Reproductive carrier screening for 110 early actionable metabolic conditions not universally included in newborn screening

A cohort of 54,119 women undergoing reproductive carrier screening identified 110 early actionable metabolic conditions (EAMCs) absent from universal newborn screening panels. Carrier frequency for at least one EAMC was 1 in 6 with the 113-gene ACMG panel and 1 in 4 with the extended 275-gene panel. The most prevalent EAMCs were phenylketonuria (1/41), congenital adrenal hyperplasia (1/57), and Wilson disease (1/63). These data support systematic integration of EAMCs into preconception or prenatal carrier screening panels to enable early postnatal intervention.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The argument is compelling: one in four women carries at least one severe but treatable metabolic disease (275-gene panel), yet absent from standard newborn screening. This study justifies reviewing carrier panel composition in France. A currently underutilized opportunity for early prenatal intervention.